NCT03897777

Brief Summary

African Americans have the greatest burden of endothelial dysfunction and hypertension. Recently, gut microbial dysbiosis (a term that describes a poorly diverse gut microbial profile and lower short-chain fatty acid (SCFA) production) has been linked to hypertension and may be involved in the pathogenesis of hypertension in African Americans. African Americans have been reported to have lower gut SCFA and SCFA can reduce blood pressure. Exercise reduces blood pressure and improves gut dysbiosis (increases SCFA) and likely couples' improvements in gut microbial health and vascular function to reduce blood pressure. Thus, the goals of this research are to fill a critical void concerning the interaction of gut dysbiosis, hypertension, and utilizing exercise to identify gut microbial adaptations that accompany a reduction in blood pressure. The short-term implications of this work will advance the clinical communities understanding of the relationship between dysbiosis and the pathogenesis of hypertension in African Americans, while long term implications will promote identifying adaptable gut microbes associated with vascular health to aid in amending treatment strategies for hypertension.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
36

participants targeted

Target at below P25 for not_applicable hypertension

Timeline
50mo left

Started Jun 2019

Longer than P75 for not_applicable hypertension

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress63%
Jun 2019Jun 2030

First Submitted

Initial submission to the registry

January 26, 2019

Completed
2 months until next milestone

First Posted

Study publicly available on registry

April 1, 2019

Completed
2 months until next milestone

Study Start

First participant enrolled

June 1, 2019

Completed
11 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2030

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2030

Last Updated

April 13, 2026

Status Verified

April 1, 2026

Enrollment Period

11 years

First QC Date

January 26, 2019

Last Update Submit

April 8, 2026

Conditions

Keywords

Blood pressureGut dysbiosisExercise training

Outcome Measures

Primary Outcomes (2)

  • Blood Pressure

    Expect a change in systolic and diastolic BP

    3 months

  • Gut Dysbiosis

    Expect an change in microbial diversity and SCFA producing microbes

    3 months

Study Arms (1)

Hypertension (Exercise Intervention)

EXPERIMENTAL

Participants with hypertension will submit blood and fecal samples for comparison to control participants with normal blood pressure. Control group will only donate fecal and blood samples and will not participate in the exercise intervention. Participants with hypertension will also perform 3 months of supervised aerobic exercise (5 days/week) and submit blood and fecal samples every 4 weeks until the completion of the study.

Behavioral: Exercise Training effect on Hypertension and Gut Dysbiosis

Interventions

the proposed research will: 1) Characterize gut microbial community structure in AA with hypertension in two important compartments that make up the overall gut bacteria in the colon (fecal and colon mucosa); 2) Quantify the relationship between aerobic exercise training and gut bacteria to identify SCFA microbes that adapt to exercise and benefit BP.

Hypertension (Exercise Intervention)

Eligibility Criteria

Age30 Years - 50 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Sedentary (regular aerobic exercise frequency ≤2 times per week and duration ≤20 minutes per session; sedentary profession);
  • years of age;
  • Control normotensive (systolic BP: 90-120 mmHg/diastolic BP: 60-80 mmHg)
  • Elevated to Stage 1 Hypertension (systolic BP: 120-129 mmHg/diastolic BP: 80-89 mmHg) and/or stage 1 hypertension (systolic BP: 130-159 mmHg/diastolic BP: 90-99 mmHg).

You may not qualify if:

  • Diagnosed with any of the following:
  • Uncontrolled hypertension, stroke, history of heart attack, heart disease;
  • Metabolic disease (diabetes mellitus);
  • Inflammatory diseases (inflammatory bowel disease(s), rheumatoid arthritis, and systemic lupus erythematosus);
  • Kidney stones or gallbladder problems;
  • Kidney disease;
  • Liver disease;
  • Lung disease;
  • Cancer within the previous 6 months; (11) pregnant females;
  • Peripheral vascular disease;
  • Taking hypertension medications or those known to affect inflammation or metabolic function (anti-inflammatories, statins, thyroid medication) in the past 1 month;
  • Currently smoking;
  • Other conditions that would exclude vigorous exercise (\>2mV ST-segment depression or CVD signs and symptoms during the screening graded exercise test).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

North Carolina A&T State University

Greensboro, North Carolina, 27411, United States

Location

MeSH Terms

Conditions

Hypertension

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular Diseases

Study Officials

  • Marc Cook, PhD

    North Carolina Agriculture & Technical State University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor of Exercise Immunology

Study Record Dates

First Submitted

January 26, 2019

First Posted

April 1, 2019

Study Start

June 1, 2019

Primary Completion (Estimated)

June 1, 2030

Study Completion (Estimated)

June 1, 2030

Last Updated

April 13, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will share

De-identifiable IPD will be made available for all primary and secondary data measures.

Shared Documents
STUDY PROTOCOL, SAP, CSR
Time Frame
Data will be available within 6 months of the end of the study

Locations